key: cord-1009703-vcz46ymn
authors: Chan, Gareth; Narang, Ashish; Aframian, Arash; Ali, Zaid; Bridgeman, Joseph; Carr, Alastair; Chapman, Laura; Goodier, Henry; Morgan, Catrin; Park, Chang; Sexton, Sarah; Sugand, Kapil; Walton, Thomas; Wilson, Michael; Belgaumkar, Ajay; Gallagher, Kieran; Ghosh, Koushik; Gibbons, Charles; Jacob, Joshua; Keightley, Andrew; Nawaz, Zuhair; Sarraf, Khaled; Wakeling, Christopher; Kieffer, William; Rogers, Benedict
title: Medium-term mortality after hip fractures and COVID-19: a prospective multi-centre UK study
date: 2021-10-29
journal: Chin J Traumatol
DOI: 10.1016/j.cjtee.2021.10.005
sha: aa95e3deeb12f2c55b544425357e9eca46660669
doc_id: 1009703
cord_uid: vcz46ymn

PURPOSE: The COVID-19 pandemic has caused 1.4 million deaths globally and is associated with a 3 to 4 times increase in 30-day mortality after a fragility hip fracture with concurrent COVID-19 infection. Typically, death from COVID-19 infection occurs between 15-22 days after the onset of symptoms, but this period can extend up to 8 weeks. This study aimed to assess the impact of concurrent COVID-19 infection on 120-day mortality after a fragility hip fracture. METHODS: A multi-centre prospective study across 10 hospitals treating 8% of the annual burden of hip fractures in England between 1st March and 30th April 2020 was performed. Patients whose surgical treatment was payable through the National Health Service Best Practice Tariff mechanism for “fragility hip fractures” were included in the study. Patients’ 120-day mortality was assessed relative to their peri-operative COVID-19 status. Statistical analysis was performed using SPSS version 27. RESULTS: A total of 746 patients were included in this study, of which 87 (11.7%) were COVID-19 positive. Mortality rates at 30 and 120-days were significantly higher for COVID-19 positive patients relative to COVID-19 negative patients (p<0.001). However, mortality rates between 31-120 days were not significantly different (p=0.107), 16.1% and 9.4% respectively for COVID-19 positive and negative patients, Odds ratio 1.855 (95% confidence interval 0.865 – 3.978). CONCLUSION: Hip fracture patients with concurrent COVID-19 infection, provided that they are alive at day-31 after injury, have no significant difference in 120-day mortality. Despite the growing awareness and concern of “long-COVID” and its widespread prevalence, this does not appear to increase medium-term mortality rates after a hip fracture.

respiratory syndrome coronavirus 2) shows no signs of abating with over 80 million cases 70 diagnosed and 1.7 million deaths globally at the time of publication. 1 The time from initial 71 symptom onset to mortality is between 2 to 8 weeks, 2 with the median time being 18.5 days 72 (IQR 15.0-22.0 days). 3 Increasing cases across Europe indicate that a "second wave" of 73 COVID-19 infections is underway in the region with daily new cases far exceeding the "first 74

wave" experienced between March -April 2020. 4 Initial trails have demonstrated promising 75 results for a vaccination; however logistical challenges with regards to its distribution and 76 public scepticism mean the associated mortality of COVID-19 will persist into the 77 foreseeable future. 5-7 78 79 International studies have reported the incidence of hip fractures with concurrent COVID-19 80 infection during the peak of the first wave of COVID-19 infections to be between 8.6% -81 18.6%. [8] [9] [10] [11] [12] Hip fractures are a significant global health burden, with 66 000 cases of fragility 82 hip fractures occurring annually in the United Kingdom, 13 This is a multicentre prospective cohort study of all consecutive patients presenting to one 102 of ten acute hospitals in South-East England with a fragility hip fracture between 1 st March 103 and 30 th April 2020. 104

Of the ten included hospitals; two are regional Level 1 Major Trauma Centres (Hospital 1  107 and Hospital 2) with the remaining eight hospitals providing district general services to their 108 local populations (Hospitals 3 -10) All hospitals provide consultant led and delivered 7-day a 109

week hip fracture care as per National Institute of Clinical Excellence Guidance. 19 110 Patients whose surgical treatment was payable through the National Health Service (NHS) 119

Best Practice Tariff mechanism for "fragility hip fractures" were included in the study. No Fig. 1 ). Our results demonstrate that despite the high incidence of long COVID in the general 232 population and its associated disabilities, this study's cohort of patients did not demonstrate 233 increased mortality rates outside the natural course COVID-19 mortality.

COVID-19 positive patients were more likely to be male, older, have extra-capsular fractures 237 and an overall greater ASA score. As compared to COVID-19 negative patients, all of four of 238 which were associated with higher mortality rates. 25, 27, 28 Conversely, this cohort of patients 239 were less likely to have an operative delay (time to theatre <36 hours from admission) 240 compared to COVID-19 negative patients, which is predictive of improved short-term 241 mortality. 29,30 However, such differences are unlikely to account for the differences in 242 overall 30 and 120-day mortality. 243 244

During the first wave of the pandemic, presentations of hip fractures continued at pre-246 pandemic rates. 14 Combined with the seasonal increase in hip fracture incidence over winter 247 months, the burden on health services will be in-line with previous years, and likely to be 248 greater than that of the first wave in the spring months. 31 Comparisons between March-249 April 2019 and March-April 2020 have shown a reduced achievement of target times to 250 surgery (<36 hours). 9,19 Operative delays of over 48-hours is a patient-independent factor 251 associated with increased 30-day mortality. 29,30 It is therefore imperative with the ongoing 252 national targets for the restoration of scheduled care within the NHS. 32 Continued attention 253 is paid on mitigating factors within clinicians' control on patient mortality after hip fractures. 254

As this study has shown, despite COVID-19 positive patients having increased short-term 255 mortality risks, provided they survive the first 30-days after admission their medium-term 256 mortality is no different to that of COVID-19 negative hip fracture patients. 

Impact-scot report on COVID-19 and hip 334 fractures

Increased mortality and major complications in hip 337 fracture care during the COVID-19 pandemic: a New York city perspective

Impact of COVID-19 on clinical outcomes for 340 patients with fractured hip

National hip fracture database (NHFD) annual report 343 2019

The effect of the COVID-19

lockdown on the epidemiology of hip fractures in the elderly: a multi-centre cohort 346 study

Nottingham Hip Fracture Score: longitudinal 348 and multi-assessment

Epidemiology and outcome after hip fracture in the 357 under 65s-evidence from the Scottish Hip Fracture Audit

Hip fracture: management -guidance and guidelines

Guidance and standard operating procedure for COVID-19 virus testing 362 in NHS laboratories

National Hip Fracture Database. Best Practice Tariff (BPT) for Fragility Hip Fracture 366

World Health Organisation

Covid-19: What do we know about "long covid"?

Rates of recovery to pre-fracture function in older 379 persons with hip fracture: an observational study

General vs. neuraxial anaesthesia 382 in hip fracture patients: a systematic review and meta-analysis

Understanding mortality rates after hip fracture 385 repair using ASA physical status in the National Hip Fracture Database

Impact of timing of surgery in elderly hip fracture 388 patients: a systematic review and meta-analysis

Association between wait time and 30-day 391 mortality in adults undergoing hip fracture